Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 6-Week, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Cariprazine in the Acute Exacerbation of Schizophrenia, With an Additional 18-Week Blinded Extension Period

NCT05368558 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT05368558
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05368558 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 6-Week, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Cariprazine in the Acute Exacerbation of Schizophrenia, With an Additional 18-Week Blinded Extension Period
Lead sponsor
AbbVie
Phase
Phase 3
Overall status
Terminated
Start date
August 18, 2022
Completion date
September 20, 2024
Enrollment
34 (actual)
Sites
52

Conditions

As the registry lists them; a condition with its own page is linked.

schizophrenia